Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

54
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
54
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

30
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
30
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

37
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
37
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

125
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
125
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

46
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
46
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

48
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
48

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Scoping review of return to work in patients with heart failure.

Heart failure reviews·2026
Same author

Spin in Systematic Reviews of Rehabilitation Journals Was High Prevalence: A Meta-Epidemiological Study.

American journal of physical medicine & rehabilitation·2026
Same author

Digital health interventions for non-older individuals at risk of frailty: A systematic review and meta-analysis.

Digital health·2025
Same author

High-intensity interval training versus moderate-intensity continuous training in patients with heart failure: a systematic review and meta-analysis.

Heart failure reviews·2023
Same author

Rehabilitation Nutrition in Patients with Chronic Kidney Disease and Cachexia.

Nutrients·2022
Same author

Relationship between Nutrition-Related Problems and Falls in Hemodialysis Patients: A Narrative Review.

Nutrients·2022

Related Experiment Video

Updated: Jul 29, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.3K

Kidney function in cachexia and sarcopenia: Facts and numbers.

Masatsugu Okamura1,2, Masaaki Konishi3, Javed Butler4,5

  • 1Berlin Institute of Health Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany.

Journal of Cachexia, Sarcopenia and Muscle
|May 24, 2023
PubMed
Summary

Cachexia and sarcopenia significantly impact patients with chronic kidney disease (CKD), increasing mortality and end-stage kidney disease risk. Accurate kidney function assessment, potentially using cystatin C, is crucial for understanding these wasting disorders in CKD.

Keywords:
CachexiaChronic kidney diseaseCystatin CProtein-energy wastingSarcopenia

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

726
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

233

Related Experiment Videos

Last Updated: Jul 29, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.3K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

726
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

233

Area of Science:

  • Nephrology
  • Geriatrics
  • Metabolic Disorders

Background:

  • Cachexia (unintentional weight loss) and sarcopenia (muscle wasting) are serious conditions impacting clinical outcomes.
  • Chronic kidney disease (CKD) is a significant contributor to these wasting disorders.
  • Protein-energy wasting (PEW) encompasses both sarcopenia and cachexia.

Purpose of the Study:

  • To review the prevalence of cachexia and sarcopenia in CKD patients.
  • To examine the relationship between these conditions and kidney function.
  • To identify optimal indicators for evaluating kidney function in CKD.

Main Methods:

  • Literature review summarizing existing studies on cachexia, sarcopenia, and CKD.
  • Analysis of kidney function assessment methods, including serum creatinine and cystatin C.
  • Examination of mortality and CKD progression data in relation to sarcopenia.

Main Results:

  • Approximately 50% of CKD patients may develop cachexia, with a 20% annual mortality rate.
  • Studies show CKD patients with sarcopenia have a 33% higher mortality hazard and are twice as likely to develop end-stage kidney disease.
  • Serum creatinine may overestimate kidney function in patients with reduced muscle mass.

Conclusions:

  • Further research is needed to rigorously define cachexia in CKD and its impact on kidney function.
  • Cystatin C and creatinine-to-cystatin-C ratio offer more accurate kidney function estimates in sarcopenic CKD patients.
  • Accurate assessment of kidney function is vital for managing cachexia and sarcopenia in CKD.